Redeye comments on Isofol’s expansion of its arfolitixorin license to include autism spectrum disorders, specifically targeting cerebral fol...
Redeye briefly comments on Isofol setting the final terms for the exercise of its TO1 warrants issued in connection with the oversubscribed ...
* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.
Redeye comments on Isofol’s study update from its ongoing phase Ib/II trial with arfolitixorin.
Redeye provides a research update following the Q4 report recently published by Isofol.
* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.
Redeye comments on Isofol’s announcement that the European Patent Office (EPO) has issued an “Intention to Grant” for a new product patent c...
Redeye provides a research update following the Q3 report published by Isofol earlier today.
Redeye comments on Isofol’s update that the second dose level in its ongoing phase Ib/II study has been completed successfully, with 200 mg/...
Redeye provides a research update following the Q2 report published by Isofol earlier today.
Redeye comments on Isofol’s recently announced rights issue outcome.
Redeye re-initiates coverage of Isofol Medical, a Swedish oncology biotech company targeting the multibillion-dollar colorectal cancer treat...
We have discontinued coverage of Isofol Medical. Our last published view, fair value range and estimates should no longer be relied upon
Redeye ceases its current coverage of Isofol Medical due to the end of the contractual period.
Redeye comments on Isofol Medical’s Q4 2022 report after shareholders voted against the board’s proposal to distribute excess cash as a divi...
Redeye comments on Isofol’s board proposing a liquidation of the company after considering different strategic alternatives.
Redeye comments on Isofol’s Q3 2022 report, and we expect the company to communicate a clearer path ahead in late Q1 2023e.
After the previously announced setback regarding the AGENT study, the Q2 report was largely in line with our expectations.
Redeye comments on Isofol’s Q2 2022 report, roughly three weeks after the company communicated that its phase III AGENT trial failed to reac...
Isofol Medical announced that the phase III trial AGENT had failed to reach its primary and most important secondary endpoints.
Redeye is disappointed by Isofol’s phase III AGENT trial failing to meet its primary ORR and key secondary PFS endpoints with statistical si...
In our view, the Q1 report was a non-event, with the results broadly in line with our estimates.
Redeye comments on Isofol’s Q1 2022 report, with the company closing in on critical AGENT top-line data.
Redeye is encouraged by Isofol starting analysis of AGENT data, with top-line data some two to four months away.
Isofol Medical released its Q4 report on 24 February.
Redeye comments on Isofol’s Q4 2021 report, with the company going into a critical period.
Late last Friday, Isofol announced that the 300 PFS events triggering the analysis of the data of the ongoing phase III study will not be re...
Isofol Medical reported a Q3 operating loss of SEK52m, fairly in line with our forecast loss of SEK49m.
Isofol Medical reported a Q2 operating loss of cSEK45m, slightly better than our expected loss of cSEK51m.
Redeye views the Q2 update on the ongoing AGENT trial as positive.
